O BSH for COVID-19 vaccine: Accurate assessments required

Kate O'Brien, director of O BSH for immunization and vaccines said at a press conference in Geneva that it is still not clear whether vaccines against COVID-19 may reduce people's ability to spread the virus.

The “is really important that we start getting more information about what vaccines do, not just about preventing the disease, but about preventing the taking of the virus,”- said O'Brien, forward the topchanel.

British pharmaceutical company AstraZeneca said on Thursday that it is co-operating with government regulators in investigating an error producing its experimental vaccine. The company has acknowledged that a lower dose of the vaccine has resulted in more effective than a full dose, according to a spokesman who spoke after AstraZeneca's chief executive chief said a further global trial was possible. The statement comes as the company prepares to provide a small amount of medicine ahead of plans to distribute 4 million doses of vaccine by the end of the year.

England-based pharmaceutical company said earlier this week that their vaccine overall was 70% effective, but there were differences between the two doses. One was 90% effective. The other was 62%. Even Pfizer and Moderna companies have announced the initial results from late-stage evidence showing their vaccines were nearly 95% effective.